Pushing radiation therapy limitations with theranostic nanoparticles
Alexandre Detappe, François Lux, Olivier Tillement

To cite this version:
Alexandre Detappe, François Lux, Olivier Tillement. Pushing radiation therapy limitations with theranostic nanoparticles. Nanomedicine, 2016, 11 (9), pp.997 - 999. 10.2217/nnm.16.38. hal-01413142

HAL Id: hal-01413142
https://hal.science/hal-01413142
Submitted on 5 Feb 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Pushing radiation therapy limitations with theranostic nanoparticles

“Nanoparticles design is a rising landscape in the era of modern oncology offering new perspectives.”

First draft submitted: 2 March 2016; Accepted for publication: 10 March 2016; Published online: 13 April 2016

Keywords: clinical trial • gadolinium • image-guided radiation therapy • radiosensitizer • theranostic nanoparticles

In radiation oncology, while radiation is effective in killing cancer cells, the dose safely deliverable to the target volume is often limited by the possibility of collateral damage to surrounding healthy tissues. However, for some cancer sites, it has been shown that a dose escalation in the tumor could significantly improve local control and patient survival [1]. While recently developed methods such as intensity-modulated radiation therapy, volumetric-modulated arc therapy and image-guided radiation therapy have improved the delivered radiation dose conformity, dose escalation remains an important clinical challenge that needs to be addressed to improve the efficacy of radiation therapy [2].

Nanoparticles design is a rising landscape in the era of modern oncology offering new perspectives. The enhancement of radiation effect induced by radiosensitizing nanoparticles is probably one of the most translational aspects. Radiosensitizing nanoparticles increase the radiobiological effects within the site of disease while maintaining the current clinical constraints on dose delivered to healthy organs. The photoelectric interaction increases strongly as a function of the atomic number of the nanoparticle (proportional to $Z^2$), giving these particles a high interaction probability with low-energy photons and allowing the formation of additional diffused photons, photoelectrons, Auger electrons and reactive oxygen species that have the potential to amplify the biological damage. Even under high-energy photon irradiation, high-Z nanoparticles can interact with primary or secondary species permitting a highly efficient nanoscale dose deposition around the nanoparticle [3]. Consequently, the differential effect between healthy tissue and tumor tissue is improved.

The efficacy of nanoparticles as radiosensitizers has been demonstrated at the preclinical level for multiple high-Z nanoparticles since Hainfeld et al. demonstrated the potential of gold nanoparticles after systemic injection [4], and at the clinical level for hafnium nanoparticles [5]. However, because of the injection method (intratumoral injection) and because of their size (50 nm), the hafnium nanoparticle applications are mainly limited to easy-to-access tumor sites, such as sarcoma, head and neck and prostate cancers. For the majority of other cancer sites, intravenous injection remains an obligation. To address these limitations while still ensuring low toxicity to the healthy tissues, theranostic nanoparticles were created, combining diagnostic and therapeutic properties.

Gadolinium is the most well-known element for biomedical applications. Its use in medicine is directly correlated with the development of contrast agents for MRI, a noninvasive and nonionizing method for acquiring volumetric images with high spatial resolution and excellent soft-tissue contrast. Some clinics have begun to replace CT simulation with MRI simulation for radiation treatment.
that the nanoparticle is nontoxic with a significant therapeutic effect, while confirming injected intravenously were attractive radiosensitizers have demonstrated that low concentrations of AGuIX Preclinical studies conducted in various tumor models issues by limiting their exposition to healthy organs. before being cleared by the kidneys, avoiding toxicity AGuIX can penetrate the tumor after a systemic injection thanks to the enhanced permeability and retention effect. The nanoparticles stay inside the tumor for a significant period of time, before being cleared by the kidneys, avoiding toxicity Preclinical studies conducted in various tumor models have demonstrated that low concentrations of AGuIX injected intravenously were attractive radiosensitizers with a significant therapeutic effect, while confirming that the nanoparticle is nontoxic. In addition, its high longitudinal relaxivity allows for better contrast properties than current US FDA-approved gadolinium chelates, creating a potential for future use in MRI-guiding radiation therapy, notably with the upcoming MR-LINAC technology.

The logical step after demonstrating the potential of AGuIX at the preclinical level for several tumor localizations is to continue the nanoparticles development to the clinical step. A current GMP manufacturing process has been developed and the regulatory toxicity tests on two animal models (rodents and monkeys) have shown no evidence of toxicity. A clinical Phase I will be investigated in France by our group in close collaboration with NH TherAguix SAS in order to determine the safety of AGuIX and its maximum tolerated dose in patients concurrently treated with standard chemoradiation; define the recommended phase II dose of AGuIX; and define the biodistribution of a single intravenous injection as well as multiple AGuIX injections in order to provide a rationale of AGuIX dosing administration. These results will demonstrate the translationality of using nanoparticles as image-guided radiation therapy agents and further clinical trial will be performed to quantify the therapeutic benefits of AGuIX. The proof-of-concept of using AGuIX as a theranostic agent in human will be a breakthrough approach for patient benefit.

Financial & competing interests disclosure
F Lux, and O Tillement have one patent to disclose: WO2011135101. This patent protects some of the nanoparticles described in this publication: AGuIX. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References
Pushing radiation therapy limitations with theranostic nanoparticles  Editorial
